Glaucoma

References

Akaike A, Tamura Y, Sato Y, et al. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol. 1993 Sep 7;241(1):1-6.

Asregadoo ER. Blood levels of thiamine and ascorbic acid in chronic open-angle glaucoma. Ann Ophthalmol. 1979 Jul;11(7):1095-100.

Campbell DG, Schertzer RM. Pathophysiology of pigment dispersion syndrome and pigmentary glaucoma. Curr Opin Ophthalmol. 1995 Apr;6(2):96-101.

Camras CB, Alm A, Watson P, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996 Nov;103(11):1916-24.

Caprioli J, Sears M, Bausher L, et al. Forskolin lowers intraocular pressure by reducing aqueous inflow. Invest Ophthalmol Vis Sci. 1984 Mar;25(3):268-77.

Duke JA. The Green Pharmacy.1997.

Filina AA, Davydova NG, Endrikhovskii SN, et al. [Lipoic acid as a means of metabolic therapy of open-angle glaucoma]. Vestn Oftalmol. 1995 Oct;111(4):6-8.

Flammer J, Haefliger IO, Orgul S, et al. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma. 1999 Jun;8(3):212-9.

Hartman HBRJEKBLKRWJrCRJPWWCPG. HP 663: a novel compound for the treatment of glaucoma. Drug Dev Res. 1988;12(3-4):197-209.

Head KA. Natural therapies for ocular disorders, part two: cataracts and glaucoma. Altern Med Rev. 2001 Apr;6(2):141-66.

Kaluza G, Strempel I, Maurer H. Stress reactivity of intraocular pressure after relaxation training in open-angle glaucoma patients. J Behav Med. 1996 Dec;19(6):587-98.

Kikuchi M, Kashii S, Honda Y, et al. Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci. 1997 Apr;38(5):848-54.

Kulkarni PS, Srinivasan BD. Cyclooxygenase and lipoxygenase pathways in anterior uvea and conjunctiva. Prog Clin Biol Res. 1989;312:39-52.

Lewith G. Complementary Medicine: An Integrated Approach.1996:108-9.

Makashova NV, Babenkova IV, Teselkin I. [The antioxidant activity of the lacrimal fluid in patients with primary open-angle glaucoma]. Vestn Oftalmol. 1999 Sep;115(5):3-4.

Mastropasqua L, Carpineto P, Ciancaglini M, et al. The effectiveness of dapiprazole in preventing exercise-induced IOP increase in patients with pigmentary dispersion syndrome. Int Ophthalmol. 1995;19(6):359-62.

Morgan J, Caprioli J, Koseki Y. Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells cocultured with astroglia. Arch Ophthalmol. 1999 Nov;117(11):1524-9.

Olney JW. Excitotoxins in foods. Neurotoxicology. 1994;15(3):535-44.

Osborne NN, Chidlow G, Nash MS, et al. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol. 1999 Apr;10(2):82-92.

Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999 Jun;43 Suppl 1:S102-S128.

Pasquali M, Still MJ, Vales T, et al. Abnormal formation of collagen cross-links in skin fibroblasts cultured from patients with Ehlers-Danlos syndrome type VI. Proc Assoc Am Physicians. 1997 Jan;109(1):33-41.

Pfister RR, Paterson CA. Ascorbic acid in the treatment of alkali burns of the eye. Ophthalmology. 1980 Oct;87(10):1050-7.

van Noort BA, Bos PJ, Klopping C, et al. Optic neuropathy from thiamine deficiency in a patient with ulcerative colitis. Doc Ophthalmol. 1987 Sep;67(1-2):45-51.

Vorwerk CK, Naskar R, Dreyer EB. [The excitotoxicity theory of glaucoma]. Klin Monatsbl Augenheilkd. 1999 Jan;214(1):2-11.

Vorwerk CK, Gorla MS, Dreyer EB. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv Ophthalmol. 1999 Jun;43 Suppl 1:S142-S150.